Atossa Genetics, Inc. Announces Pricing of Initial Public Offering and Commencement of Trading

SEATTLE, WA--(Marketwire - Nov 8, 2012) -  Atossa Genetics, Inc. (NASDAQ: ATOS) (the "Company") announced today the pricing of its firm commitment, underwritten initial public offering of 800,000 shares of its common stock at a price of $5.00 per share. In addition, the underwriters were granted a 45-day option to purchase up to an additional 120,000 shares to cover over-allotments, if any. All of the shares in the offering are being sold by Atossa. Atossa's common stock will commence trading on the NASDAQ Capital Market under the trading symbol "ATOS" on November 8, 2012.

Dawson James Securities, Inc. is the sole book-running manager for this offering. This offering is being made only by means of a prospectus. A copy of the final prospectus relating to this offering may be obtained by contacting Monique Maclaren of Dawson James Securities, Inc. at (561) 391-5555 or by emailing mmaclaren@dawsonjames.com or by standard mail at 925 S. Federal Highway, Suite 600, Boca Raton, FL 33432. You may also obtain these documents for free by visiting EDGAR on the SEC's website at http://www.sec.gov.

A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission as of November 7, 2012. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Atossa Genetics, Inc.

Atossa Genetics, Inc., The Breast Health Company, is based in Seattle, Washington, and is focused on the prevention of breast cancer through the commercialization of diagnostic medical devices and tests that can detect precursors to breast cancer, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.